

**SLC22A16 Antibody (N-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP17568a****Specification**

---

**SLC22A16 Antibody (N-term) Blocking Peptide - Product Information**Primary Accession [Q86VW1](#)**SLC22A16 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 85413**Other Names**

Solute carrier family 22 member 16, Carnitine transporter 2, CT2, Fly-like putative transporter 2, FLIPT2, Flipt 2, Organic cation transporter OKB1, Organic cation/carnitine transporter 6, SLC22A16, OCT6

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**SLC22A16 Antibody (N-term) Blocking Peptide - Protein Information****Name** SLC22A16 ([HGNC:20302](#))**Synonyms** OCT6**Function**

Facilitative organic cation transporter that mediates the transport of carnitine as well as the polyamine spermidine (PubMed: [12089149](http://www.uniprot.org/citations/12089149), PubMed: [20037140](http://www.uniprot.org/citations/20037140)). Mediates the partially Na(+)- dependent bidirectional transport of carnitine (PubMed: [12089149](http://www.uniprot.org/citations/12089149)). May mediate L-carnitine secretion from testis epididymal epithelium into the lumen which is involved in the maturation of spermatozoa (PubMed: [12089149](http://www.uniprot.org/citations/12089149)).

**Cellular Location**

Cell membrane; Multi-pass membrane protein. Note=Detected in the plasma membrane of Sertoli cells and in the luminal membrane of epithelial cells in the epididymis

**Tissue Location**

Expressed in testis and epididymis (at protein level) (PubMed:12384147, PubMed:12089149, PubMed:15963465). Expressed in endometrium (at protein level); highly expressed during the normal secretory phase, but expression is significantly reduced in the proliferative phase (PubMed:17197897). Expressed at lower levels in adult tissues including bone marrow (at protein level) (PubMed:12372408, PubMed:12384147, PubMed:15963465). Expressed in hematopoietic cells, including CD34(+) leukocytes (PubMed:12384147) Expressed in fetal liver (at protein level), brain, lung, kidney, heart, skeletal muscle, spleen and thymus (PubMed:12372408, PubMed:12384147, PubMed:15963465). Expressed in leukemia cells (PubMed:12384147). Abundantly expressed in ovarian cancer clear-cell adenocarcinoma (PubMed:17581421).

### **SLC22A16 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **SLC22A16 Antibody (N-term) Blocking Peptide - Images**

### **SLC22A16 Antibody (N-term) Blocking Peptide - Background**

Organic ion transporters, such as SLC22A16, transport various medically and physiologically important compounds, including pharmaceuticals, toxins, hormones, neurotransmitters, and cellular metabolites. These transporters are also referred to as amphiphilic solute facilitators (ASFs).

### **SLC22A16 Antibody (N-term) Blocking Peptide - References**

Liu, C.Y., et al. Carcinogenesis 31(7):1259-1263(2010) Bray, J., et al. Br. J. Cancer 102(6):1003-1009(2010) Aouida, M., et al. J. Biol. Chem. 285(9):6275-6284(2010) Ota, K., et al. Int. J. Gynecol. Pathol. 26(3):334-340(2007) Lal, S., et al. Pharmacogenomics 8(6):567-575(2007)